Synthesis and targeting of gold-coated 177 Lu-containing lanthanide phosphate nanoparticles-A potential theranostic agent for pulmonary metastatic disease

Targeted radiotherapies maximize cytotoxicity to cancer cells. In this work, we describe the synthesis, characterization, and biodistribution of antibody conjugated gold-coated lanthanide phosphate nanoparticles containing Lu. [ Lu]Lu Gd (PO )@Au@PEG @Ab nanoparticles combine the radiation resistanc...

Full description

Saved in:
Bibliographic Details
Published in:APL bioengineering 2018-03, Vol.2 (1), p.016101
Main Authors: Sobol, Nicholas, Sutherlin, Logan, Cedrowska, Edyta, Schorp, Joshua, Rodríguez-Rodríguez, Cristina, Sossi, Vesna, Lattimer, Jimmy, Miller, Douglas C, Pevsner, Paul, Robertson, J David
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted radiotherapies maximize cytotoxicity to cancer cells. In this work, we describe the synthesis, characterization, and biodistribution of antibody conjugated gold-coated lanthanide phosphate nanoparticles containing Lu. [ Lu]Lu Gd (PO )@Au@PEG @Ab nanoparticles combine the radiation resistance of crystalline lanthanide phosphate for stability, the magnetic properties of gadolinium for facile separations, and a gold coating that can be readily functionalized for the attachment of targeting moieties. In contrast to current targeted radiotherapeutic pharmaceuticals, the nanoparticle-antibody conjugate can target and deliver multiple beta radiations to a single biologically relevant receptor. Up to 95% of the injected dose was delivered to the lungs using the monoclonal antibody mAb-201b to target the nanoparticles to thrombomodulin receptors. The 208 keV gamma ray from Lu decay (11%) can be used for SPECT imaging of the radiotherapeutic agent, while the moderate energy beta emitted in the decay can be highly effective in treating metastatic disease.
ISSN:2473-2877